BTIG analyst Mark Massaro reiterated a Hold rating on T2 Biosystems (TTOO – Research Report) yesterday. The company’s shares closed yesterday at $0.17.
Massaro covers the Healthcare sector, focusing on stocks such as CareDx, BioNano Genomics, and Akoya Biosciences. According to TipRanks, Massaro has an average return of -7.2% and a 38.99% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for T2 Biosystems with a $0.58 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on T2 Biosystems’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.48 million and a GAAP net loss of $10.1 million. In comparison, last year the company earned a revenue of $7.23 million and had a GAAP net loss of $16.5 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types. It products include T2Bacteria Panel, T2Candida Panel, T2Dx Instrument, AND T2MR Technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.
Read More on TTOO:
- T2 Biosystems Announces First Quarter 2023 Financial Results
- T2 Biosystems Announces FDA 510(k) Submission for the T2Biothreat Panel
- T2 Biosystems Announces Exploration of Strategic Alternatives and the Implementation of a Restructuring Program
- T2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 23, 2023
- T2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 22, 2023
